Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer: Translating Evidence to Clinical Practice - Episode 4

Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

, ,

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.